Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Would rather have my mum sitting here now than having to go and put flowers on her grave we not all thinking about share price
Thank you for contacting Panorama and apologies for the automated response. As you can hopefully appreciate, we receive hundreds of emails everyday and we cannot reply individually to each one. We can, however, assure you that every one is read.
If you would like to join the conversation about Panorama you could try our social media platforms:
https://www.facebook.com/bbcpanorama/
https://www.instagram.com/bbcpanorama/
https://twitter.com/BBCPanorama
https://www.youtube.com/user/BBCPanorama
Just sent email to panorama.reply@bbc.co.uk lets all do this telling them whats going on to get them to bring it to the publics attention on the millions being wasted every day lets not just post on here lets make a difference its not a bout share price but lives of our loved ones and friends
I had covid March 2020 and suffering long covid still been feel more worst last few days spoke to doctors yesterday told me to do a test in case i have caught it again already have double vaccine. I told doctor that i did a test at home yesterday negative (as girlfriend works for NHS and gets them to do ) in my doctors words them test kits are as about as good as a chocolate fire guard as 1 in 3 chance of correct result cheapest rubbish the Government could find. So told me to order PCR test kit online coming today. So that's what GP's think of them and great lets buy more we must be getting down to our last 50 container full sitting around in the docks with other containers full of sub stranded PPE !!!!
We are all hope share prices to raise aa moan at each other on here with some silly posts but we need to remember behind our gains their are a lot of lives lost to early , families torn apart, love ones in nursing homes we can not cuddle who raised us and gave the reassuring cuddles when we need them in growing up if life. Yes i know we are all in it to make money and the government seem to like a rabbit in a cars head lights and are not looking closer to home what companies have developed the government has never had to deal with such a pandemic which is world wide yes they should of done things earlier but its easy after the event we could have a president who flies to disaster zone where a million acres have been destroyed and homes lost and more importantly lives and he turned around and blamed forestry management he's been telling them for years to them this !!!!!
Yes i am invested in stock related companies to make money but do give back to others effected and the unemployment figure if we have a stock that rise like that will in the next few months coming we would be happy and with Christmas coming families are going to need support and mental heath will be a big part as if you were the bread earner for the family
and got laid off you have set your life to suit saving a few pound a month for a rainy day but not a drought how that persons mental health is effected can have tragic end my best friends wife phoned me few months ago and told me her husband would not leave the bedroom for days he never missed a day off for illness but he could not see how his life was going to be able to go on i been there for another reason and got great help but with all in lock down he could not get that help but he had a good wife and i spent time with him going through what i had learnt from going through it and he's now back at work like nothing had happen but how many will not have that support network so look out for your family and friends as they try to put a front on until one day they will crack just be their for them. sorry to go on but after read some of the post on this and other pages we sometime need a reality check
This was posted my another person on another board :
I’m posting because I saw on this mornings news
that there are theatre companies that are already testing using the FRANKD test which doesn’t need a lab for results and also get the results via an app 45mins later.
Avacta Group plc
Avacta has announced its appointment of BBI Solutions, part of BBI Group (‘BBI’),
to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being
developed with its partner, Cytiva (formerly part of GE Healthcare Life Sciences).
This follows news from 22 April 2020 , that the partnership had progressed rapidly
with several highly specific Affimer®
reagents having already been successfully
generated. Anticipating very high demand for the test, BBI has now been selected
as a preferred manufacturing partner, while Avacta also continues discussions
with other high volume producers with a view to ensuring access to additional
capacity that may be needed to address global needs both now and in the future.
Developing a potential ‘game changing’ product
Simplicity, scale and early detection are all critical factors that have to be
considered by users seeking rapid testing and diagnostics as a positive step
towards controlling the current global health crisis. Improvements in ease of use
created through the Avacta-Cytiva partnership, which offer rapid, reliable testing
while eliminating the invasive nasopharyngeal swab protocol without
compromising performance, has potential to become a ‘game changer’ in the next
phase of the global pandemic response.
Realistically, the offer of mass testing with low cost disposable tests, whilst also
eliminating the expense/complexity of extraction through provision of a less
invasive sample collection process, is most likely to open testing access to wider
global communities. Indeed, given that most government agencies/health
practitioners consider frequent testing of a large percentage of the population to be
the best path forward, and critical for getting the global economy back to work, the
near and longer-term market opportunity presented is clearly very large indeed.
Appointing the ideal manufacturer
BBI Solutions is a leading global developer and manufacturer of raw materials and
finished test products for the in-vitro diagnostics market, with manufacturing sites
in five different countries, spanning four continents. The manufacturing
agreement between Avacta and BBI comprises the accelerated development and
validation of a scaled-up manufacturing process that has the potential to ramp up
to a production capacity of millions of tests per month. Avacta, Cytiva and BBI are
now undertaking a technology transfer that covers the prototype along with the
related manufacturing procedures for the saliva-based test.
Closing in on a major inflection point?
Having recently put the necessary financial resources in place, Avacta now
appears to be rapidly closing in on a number of major inflection points. While
timing remains of the essence for any COVID-19 test developments, billion-dollar
markets are available right now to first movers capable of delivering an approved
antigen testing product that comes with the necessary scale, reliability and ease
of use.
Avacta Group plc
Avacta has announced an extension to its collaboration and license agreement
with Daewoong Pharmaceutical Co. Ltd. (KSX: 069620, ‘Daewoong’). AffyXell
Therapeutics, the joint venture established in South Korea by the two companies,
will now also undertake research covering the SARS-COV-2 neutralising Affimer
molecules for the treatment of COVID-19, while also ensuring that it is prepared
for rapid development of similar therapies for future global pandemics. Given that
the JV’s research & development costs are fully funded by Daewoong, Avacta has
effectively established a low-cost means by which to actively participate in the
exciting field of cell and gene therapy, while still retaining all therapeutic right to
Affirmers outside these areas. Although AffyXell is still a young business, the
direction of resources, IP and timely application by its founding companies
suggests opportunity for substantial value creation exists. Possibly this was best
highlighted in a recent white paper by Pharma Intelligence that detailed
acquisitions of such early clinical stage assets being completed in the range of
US$1bn to US$5bn over the past 12 months.
Expanding the scope of the partnership
AffyXell Therapeutics, the next-generation cell and gene therapy joint venture
between Avacta (45%) and Daewoong Pharmaceutical (55%) established in January
2020, has been developing a novel class of mesenchymal stem cell (‘MSC’)
treatments that are engineered to also produce Affimer therapies in the patient at
the site of action. Their potential is for application to a wide range of inflammatory
and autoimmune diseases, while also ideally demonstrating the power of Affimer
proteins in the field of engineered cell therapies. The ultimate objective originally
cited by the joint venture is to create capability to fully address severe and lifethreatening conditions, such as inflammatory bowel diseases and multiple
sclerosis, as well as other autoimmune diseases.
The expansion of the agreement announced today extends the scope of the
partnership to include Affimer molecules that target viruses, such as
coronaviruses, in order to develop therapies that repair the lung damage caused by
COVID-19, whilst also producing neutralising Affimer molecules to prevent the
progression of the disease. The work will allow AffyXell to develop expertise in
order to rapidly develop next-generation stem cell therapies for future infectious
respiratory disease outbreaks. This expertise could also be applied to other severe
respiratory conditions resulting from an overactive immune response, such as
chronic obstructive pulmonary disorder (‘COPD’) and idiopathic pulmonary fibrosis
(‘IPF’).
Approaching a major inflection point?
Having recently put the necessary financial resources in place, Avacta now
appears positioned to reach a number of major inflection points. While timing
remains of the essence for any COVID-19 therapeutic development, the